Oversubscribed Initial Public Offering on Euronext Paris for HealthCap portfolio company Cerenis Therapeutics

HealthCap portfolio company Cerenis Therapeutics SA has successfully completed its book building for an Initial Public Offering on Euronext Paris (ticker: “CEREN”). The offering was covered several times and the final pricing was EUR 12.70 per share, at the top of the indicated price range. Cerenis Therapeutics is raising EUR 53 million in gross proceeds and will have a market capitalization of approximately EUR 226 million. The shares will commence trading on March 30, 2015. HealthCap has been one of the two main shareholders in Cerenis Therapeutics since the start of the company in 2005.

Cerenis Therapeutics is a French company focusing on treatment of cardiovascular and metabolic diseases. Cerenis is developing HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients, and drugs that increase HDL in patients with low HDL. The company has built a clinical stage pipeline of products based on the reverse lipid transport pathway, which facilitates the elimination of cholesterol.

For more information, please visit http://cerenis-corp.com/